Perng C L, Lin H J, Lee S D
Department of Medicine, Veterans General Hospital-Taipei, Taiwan, R.O.C.
Zhonghua Yi Xue Za Zhi (Taipei). 1994 Aug;54(2):82-6.
Although many tumor markers can detect gastric cancer, they are still far from perfect. The aim of this study was to evaluate the role of a new tumor marker, serum c-erbB-2 oncoprotein, in patients with gastric cancer.
We tested this tumor marker in 35 patients of gastric cancer, 13 patients of hepatoma, 13 patients of colon cancer, 8 patients of lung cancer, and 22 patients without malignancy (4 of acute pancreatitis, 10 of benign gastric ulcer and 8 normal subjects) between July and December 1991. A newly developed enzyme immunoassay kit was used to assay serum c-erbB-2 oncoprotein.
Abnormal level of c-erbB-2 oncoprotein was found in 11/32 (34.4%) of gastric cancer, 4/13 (30.8%) of hepatoma, 2/8 (25%) of lung cancer, 3/13 (23.1%) of colon cancer, 0/3 (0%) of gastric lymphoma, and 4 of non-malignant conditions (18.2%). Six tumor markers were assessed at the same time in 32 patients of gastric cancer. The abnormal level for CA 19-9 was found in 13/32 patients (40.6%); for TPA: 9/32 (28.1%); for c-erbB-2 oncoprotein: 11/32 (34.4%); for CEA: 8/32 (25%); for CA 125: 2/32 (6.3%); and for AFP: 1/32 (3.1%).
C-erbB-2 oncoprotein is a new tumor marker. Practical application needs further mass survey.
尽管许多肿瘤标志物可检测胃癌，但它们仍远非完美。本研究的目的是评估一种新的肿瘤标志物——血清c-erbB-2癌蛋白在胃癌患者中的作用。
1991年7月至12月期间，我们对35例胃癌患者、13例肝癌患者、13例结肠癌患者、8例肺癌患者以及22例无恶性肿瘤的患者（4例急性胰腺炎患者、10例良性胃溃疡患者和8例正常受试者）检测了这种肿瘤标志物。使用一种新开发的酶免疫分析试剂盒检测血清c-erbB-2癌蛋白。
在胃癌患者中，11/32（34.4%）的患者c-erbB-2癌蛋白水平异常；肝癌患者中为4/13（30.8%）；肺癌患者中为2/8（25%）；结肠癌患者中为3/13（23.1%）；胃淋巴瘤患者中为0/3（0%）；非恶性疾病患者中有4例（18.2%）。对32例胃癌患者同时检测了六种肿瘤标志物。CA 19-9水平异常的患者有13/32（40.6%）；组织多肽抗原（TPA）为9/32（28.1%）；c-erbB-2癌蛋白为11/32（34.4%）；癌胚抗原（CEA）为8/32（25%）；癌抗原125（CA 125）为2/32（6.3%）；甲胎蛋白（AFP）为1/32（3.1%）。
c-erbB-2癌蛋白是一种新的肿瘤标志物。其实际应用需要进一步的大规模调查。
